Retatrutide
Triple agonist hitting the GIP, GLP-1 and glucagon receptors. The newest name in incretin research.
from $61.955 mg / 10 mg / 30 mg / 50 mg / 60 mg
5-Amino-1MQ
Small molecule, not a peptide. Inhibits NNMT and shows up in NAD+ salvage and adipocyte research.
size
pack
- Form
- Powder (small molecule)
- Molecular weight
- 173.2 g/mol (cation)
- CAS
- 42464-96-0
- Storage
- −20 °C, dark, dry
- Lab report
- COA by lot
Where it shows up in research
- NNMT inhibition
- NAD+ salvage pathway
- Adipocyte metabolism
Research use only. Sold for in-vitro lab work. Not for human or veterinary use, not approved by Health Canada, no DIN. MW and CAS are literature values for the base compound; the lot's COA is the final word.
More metabolic
Tirzepatide
Dual GIP / GLP-1 receptor agonist. A workhorse compound for incretin and metabolic study designs.
from $53.9510 mg / 15 mg / 20 mg / 30 mg / 60 mg
Semaglutide
GLP-1 receptor agonist with a fatty-acid side chain for albumin binding. The common reference compound.
from $40.955 mg / 10 mg / 20 mg
Cagrilintide
Long-acting amylin analogue, often studied next to GLP-1 agonists in combination designs.
from $47.955 mg / 10 mg